Status:
COMPLETED
Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment
Lead Sponsor:
Laboratoires Thea
Collaborating Sponsors:
Iris Pharma
Conditions:
Dry Eye
Eligibility:
All Genders
18+ years
Brief Summary
Multi-centre, international, non-interventional, prospective survey
Detailed Description
To assess after 84 days, on a large scale patient population, the evaluation of ocular surface diseases and the satisfaction of dry eye disease (DED) treatment naïve patients or those who had to switc...
Eligibility Criteria
Inclusion
- All dry eye patients who require artificial tears or need to change their current artificial tears for any reason (i.e. due to dissatisfaction or low efficacy, etc…)
- Outpatients of either sex, aged at least 18 years
- Patients informed of the objectives of the survey and agreeing to participate.
Exclusion
- Use of cyclosporine, lifitegrast, tacrolimus, sirolimus within last 3 months and during the survey
- Use of topical ophthalmological treatments (glaucoma, etc…)
- Use of lacrimal plugs
- Ocular surgery in the last 12 months
- Concomitant use of corticosteroids
- Concomitant use of autologous serum or any blood derivatives
- Severe blepharitis
- Severe dry eye associated to
- Eyelid malposition
- Corneal dystrophy
- Ocular neoplasia
- Sjogren syndrome
- Any systemic pathologies
- Pregnancy/lactation
Key Trial Info
Start Date :
April 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2020
Estimated Enrollment :
310 Patients enrolled
Trial Details
Trial ID
NCT04803240
Start Date
April 1 2019
End Date
March 30 2020
Last Update
March 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Plymouth
Plymouth, United Kingdom